secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001213900-22-070348
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX Q3 net loss $6.8M; BX004 Part 1 results expected Q1 2023, cash through mid-2024
--------------------------------------------------------------------------------

- Cash $41.5M as of Sep 30, 2022; cash runway through at least mid-2024.
- Net loss $6.8M vs $10M in Q3 2021; R&D expenses $3.5M (down from $6.6M) due to restructuring.
- BX004 Phase 1b/2a Part 1 results expected Q1 2023; Part 2 results Q3 2023.
- CF Foundation equity award up to $5M; second $2M tranche upon Part 1 dosing completion.
- Published Cell paper on phage proof-of-concept for inflammatory bowel disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390022070348/0001213900-22-070348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390022070348/ea168308-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-070348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer